Article

Detection and genetic analysis of β-thalassemia mutations by competitive oligopriming

Laboratory of Biology Medical Faculty, University of Patras, Greece.
Human Mutation (Impact Factor: 5.05). 01/1995; 6(1):30-5. DOI: 10.1002/humu.1380060107
Source: PubMed

ABSTRACT A new approach for the detection of beta-thalassemia mutations has been applied, based on competitive oligonucleotide priming (COP) of in vitro DNA amplification at the mutation site. This method allows genotyping of the template DNA, through differential labeling of the allele-specific competitive oligoprimers and biotinylation of the common reverse primer. The system provides a basis for rapid, simple, and reliable detection of the numerous known beta-thalassemia mutations, revealing the precise nature of the mismatch in each case, and thereby facilitating the molecular genetic analysis of the disease.

0 Followers
 · 
74 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have developed an assay for the rapid screening of point mutations in specific genes. Our assay is based upon competitive hybridization of differentially labeled wild-type and mutant oligonucleotide probes to a PCR-generated DNA template and a subsequent analysis of the mobility of the probe-template hybrids. The assay is referred to as a competitive mobility shift assay. Generation of a hybridization stringency gradient allows perfect-matched hybrids to be formed to a greater extent at a slightly higher stringency than the corresponding mismatched hybrids. The stringency gradient is achieved by carrying out the hybridizations at a steadily decreasing temperature (from 95 to 20 degrees C) in a thermal cycler. This step allows the assay to be competitive while avoiding the need to establish precise hybridization conditions for each gene-specific probe, a major disadvantage associated with reverse oligonucleotide hybridization. The assay is rapid and sensitive and can selectively detect mutant DNA in the presence of a large (up to one million-fold) excess of wild-type DNA.
    Analytical Biochemistry 08/1996; 239(1):61-9. DOI:10.1006/abio.1996.0291 · 2.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe the evaluation of the Bio-Rad BeTha Gene 1 kit (Bio-Rad Laboratories, Hercules, CA), a DNA-probe assay designed for the qualitative determination of the eight most common Mediteranean β-thalassemia mutations. The kit utilizes the principle of allele-specific oligonucleotide (ASO) hybridization. Following sample preparation and in vitro DNA amplification by the polymerase chain reaction (PCR), an allele-specific detection of the amplified products by a nonradioactive enzymatic assay is performed. Genomic DNA is prepared from an individual's whole blood with a DNA purification matrix. In a second step, the β-globin gene is amplified in a multiplex PCR reaction containing four 5′ biotinylated oligonucleotide primers. In a final step, an aliquot of the PCR reaction is first chemically denatured and then captured in two eight-well strips of a 96-well enzyme-linked immunosorbent assay (ELISA) plate by hybridization to an immobilized ASO probe. Each DNA sequence at each of the eight mutation sites is represented by one normal and one mutant ASO. During this capture/hybridization step, which is performed at 37°C, only perfectly matched PCR products will be captured by an ASO. Subsequently, the allele-specific captured biotin-labeled PCR products are detected by a colorimetric enzymatic reaction. The system permits the detection of 16 β-thalassemia alleles using a high-throughput format that can be automated easily. A clinical feasibility study was performed to evaluate the functionality (method camparison study, assay validity using samples previously collected and stored at various temperatures for different periods of time, interference on kit performance, and assay validity for prenatal diagnosis) and the usability (ease of use, sample throughput) of the kit. The analysis of 110 samples previously studied with reference methods showed 100% clinical sensitivity and specificity. We demonstrate here that the procedure not only increases the throughput of β-thalassemia allele genotyping but also provides an accurate, rapid, reliable, and nonisotopic diagnostic tool. Am. J. Hematol. 59:214–222, 1998. © 1998 Wiley-Liss, Inc.
    American Journal of Hematology 11/1998; 59(3):214-222. DOI:10.1002/(SICI)1096-8652(199811)59:33.0.CO;2-Z · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We describe the evaluation of the Bio-Rad BeTha Gene 1 kit (Bio-Rad Laboratories, Hercules, CA), a DNA-probe assay designed for the qualitative determination of the eight most common Mediterranean beta-thalassemia mutations. The kit utilizes the principle of allele-specific oligonucleotide (ASO) hybridization. Following sample preparation and in vitro DNA amplification by the polymerase chain reaction (PCR), an allele-specific detection of the amplified products by a nonradioactive enzymatic assay is performed. Genomic DNA is prepared from an individual's whole blood with a DNA purification matrix. In a second step, the beta-globin gene is amplified in a multiplex PCR reaction containing four 5' biotinylated oligonucleotide primers. In a final step, an aliquot of the PCR reaction is first chemically denatured and then captured in two eight-well strips of a 96-well enzyme-linked immunosorbent assay (ELISA) plate by hybridization to an immobilized ASO probe. Each DNA sequence at each of the eight mutation sites is represented by one normal and one mutant ASO. During this capture/hybridization step, which is performed at 37 degrees C, only perfectly matched PCR products will be captured by an ASO. Subsequently, the allele-specific captured biotin-labeled PCR products are detected by a colorimetric enzymatic reaction. The system permits the detection of 16 beta-thalassemia alleles using a high-throughput format that can be automated easily. A clinical feasibility study was performed to evaluate the functionality (method comparison study, assay validity using samples previously collected and stored at various temperatures for different periods of time, interference on kit performance, and assay validity for prenatal diagnosis) and the usability (ease of use, sample throughput) of the kit. The analysis of 110 samples previously studied with reference methods showed 100% clinical sensitivity and specificity. We demonstrate here that the procedure not only increases the throughput of beta-thalassemia allele genotyping but also provides an accurate, rapid, reliable, and nonisotopic diagnostic tool.
    American Journal of Hematology 12/1998; 59(3):214-22. · 3.48 Impact Factor
Show more